Pharmaceutical giants Eli Lilly and Novo Nordisk have significantly upgraded their financial outlook for 2026, driven by robust demand for their popular weight-loss and diabetes drugs. Eli Lilly, on August 5, 2026, increased its full-year revenue guidance from an initial range of $82 billion-$85 billion to a new range of $85 billion-$87 billion. The company also adjusted its performance margin forecast from 47.0%-48.5% to 49.0%-50.5% and slightly narrowed its earnings per share (EPS) guidance from $35.50-$37.00 to $35.50-$36.50. This positive revision comes after Eli Lilly reported Q2 2026 worldwide revenue of $23.0 billion, surpassing analyst expectations, largely due to strong sales of its diabetes and weight-loss drugs.
Similarly, Novo Nordisk, on August 4, 2026, raised its full-year adjusted sales and adjusted operating profit outlook for 2026. The company now expects adjusted sales growth to be between 0% and -6% at constant exchange rates (CER), an improvement from its prior forecast of -4% to -12%. Its adjusted operating profit growth is also projected to be in the range of 0% to -6% at CER, up from the previous -4% to -12%. This improved guidance is primarily attributed to increased expectations for GLP-1 product sales, particularly the continued rapid adoption of its Wegovy® pill in the US, which has garnered over 5 million prescriptions since its launch, alongside strong international growth and the introduction of Wegovy® HD.
In Q2 2026, Novo Nordisk reported adjusted sales of DKK 78,488 million, representing a 7% growth at CER, and adjusted operating profit of DKK 33,389 million, an 11% increase at CER. The company highlighted that its Wegovy® product portfolio remains a key driver for growth, with new EMA approvals in July for Wegovy® 7.2 mg single-dose pen and Wegovy® pill for obesity. The company also acknowledged a non-recurring, non-cash impairment charge of DKK 6.3 billion related to intangible pipeline assets in Q2 2026, which impacted its reported operating profit.
Both companies' updated forecasts reflect the significant and growing market for GLP-1 agonists. Analysts are closely watching how these pharmaceutical giants will manage the expanding demand, manufacturing capacity, and potential competition in this lucrative segment. The strong performance of their weight-loss and diabetes drugs has solidified their positions as leaders in a rapidly evolving therapeutic area, with significant implications for future revenue streams.
